Don't agree at all. Nigel is an excellent executive and is realigning the company to the necessary proper path a serious biotech company needs to take. The previous CEO was a short cutter. If Nigel had 50 million in the bank instead of 10, this company would be a miniSirtex in 3 years. The German strategy is nearly there - they could be selling 100s of treatments there once the trial is funded.
I have no idea about Leedman but he seems to talk himself up a lot.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.015(1.48%) |
Mkt cap ! $14.65M | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.05 | 95.0¢ | $109.7K | 112.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23906 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 2292 | 2 |
View Market Depth
| Last trade - 15.57pm 19/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |